Managing type 2 diabetes in older adults remains a clinical challenge—particularly when balancing glycemic efficacy with safety. Many middle-aged and elderly patients struggle to achieve target glucose levels despite being on one or two oral antihyperglycemic agents. This difficulty stems not only from progressive beta-cell dysfunction but also from age-related physiological changes: reduced hepatic and renal clearance, increased susceptibility to hypoglycemia, atypical symptom presentation, higher prevalence of comorbidities and diabetes-related complications, and diminished capacity for self-management.
Clinical guidelines consistently emphasize that hypoglycemia risk should be a primary consideration when selecting glucose-lowering therapy for older adults. Drugs associated with significant insulin secretion stimulation—or those with narrow therapeutic windows—pose unacceptable risks in this population. Consequently, agents with low intrinsic hypoglycemia potential, favorable pharmacokinetic profiles, and minimal drug–drug interaction concerns are strongly preferred.
Among emerging therapeutic options, mulberry twig alkaloids (MTA) tablets represent a novel, domestically developed, multi-target oral antidiabetic agent approved in China. Derived from the twigs of the white mulberry tree—a byproduct of sericulture—MTA is standardized to contain bioactive alkaloids, including 1-deoxynojirimycin and its derivatives. Its primary mechanism involves highly selective inhibition of intestinal alpha-glucosidase, thereby delaying carbohydrate digestion and absorption. This action effectively blunts postprandial glucose excursions—a key contributor to overall glycemic burden in older adults.
Importantly, MTA extends beyond simple enzyme inhibition. Preclinical and clinical evidence supports additional pleiotropic effects: modulation of dyslipidemia, enhancement of antioxidant defenses, protection of pancreatic beta-cells, improvement of glucose-stimulated insulin secretion, and stimulation of glucagon-like peptide-1 (GLP-1) release. Notably, unlike first-generation alpha-glucosidase inhibitors such as acarbose, MTA demonstrates significantly lower gastrointestinal tolerability issues—clinical trials report nearly a 50% reduction in adverse events like flatulence and abdominal discomfort.
Robust clinical data reinforce its utility in older populations. A randomized, multicenter trial demonstrated that MTA monotherapy significantly improved both 1-hour and 2-hour postprandial glucose levels in elderly patients with suboptimally controlled type 2 diabetes—without increasing hypoglycemia or other serious adverse events. In combination therapy, MTA added to continuous subcutaneous insulin infusion (CSII) yielded superior glycemic stability: patients experienced reduced glycemic variability, lower daily insulin requirements, and shorter hospital stays—all while maintaining an acceptable safety profile.
Given its targeted mechanism, favorable tolerability, low hypoglycemia risk, and growing body of clinical evidence, mulberry twig alkaloids tablets offer a compelling therapeutic option for middle-aged and older adults with type 2 diabetes—especially those requiring safer, effective alternatives to conventional oral agents.